Gaucher Disease

Gaucher Disease (GBA) Sequencing 3001648
Method: Polymerase Chain Reaction/Sequencing

Carrier screening or diagnostic testing for GD in individuals of non-Ashkenazi Jewish descent

Gaucher Disease (GBA), 8 Variants 0051438
Method: Polymerase Chain Reaction/Fluorescence Monitoring

Carrier screening or diagnostic testing for GD in individuals of Ashkenazi Jewish descent

Familial Mutation, Targeted Sequencing 2001961
Method: Polymerase Chain Reaction/Sequencing

Useful when pathogenic familial variants identifiable by sequencing are known

Related Tests

Use to diagnose GD only; not accurate for carrier screening

Ashkenazi Jewish Diseases, 16 Genes 0051415
Method: Polymerase Chain Reaction/Fluorescence Monitoring

Preferred gene panel for carrier screening in individuals of Ashkenazi Jewish descent

For test specific information, see Ashkenazi Jewish Genetic Diseases Panel Test Fact Sheet

Gaucher disease (GD) is a lysosomal storage disease most often affecting individuals of Ashkenazi Jewish (AJ) descent. GD type 1 is the most common form with symptoms ranging from mild to severe. Symptoms include hepatosplenomegaly, anemia, thrombocytopenia, lung disease, and bone abnormalities. Symptoms of type 1 can appear anytime from childhood to adulthood. GD types 2 and 3 are neuronopathic forms differentiated mainly by disease progression and involve the central nervous system with life-threatening problems that typically appear in early infancy. Symptoms of types 2 and 3 also include eye abnormalities, seizures, and damage to the brain. Testing is used for prepregnancy carrier screening or for diagnostic testing in individuals suspected of having GD.

Disease Overview


  • ~1 in 57,000 to 1 in 75,000   in general population
  • GD type 1 estimated at 1 in 855 in individuals of AJ descent 

Age of Onset

  • Type 1: childhood/adulthood
  • Type 2: typically before age 2, with death by age 2-4
  • Type 3: typically in childhood, but survival into third or fourth decade


GD affects lysosomal storage and has extreme symptom variability, ranging from perinatal lethality to asymptomatic individuals.

  • Type 1
    • Represents 95% of GD; characterized by non-neuronopathic symptoms including bone disease, hepatosplenomegaly, lung disease, and anemia 
  • Type 2 (acute neuronopathic)
    • Primary central nervous system (CNS) involvement with rapidly progressive course
  • Type 3 (subacute/chronic)
    • Primary CNS involvement with slowly progressive course





Autosomal recessive



Test Methodology

  • GBA sequencing: Long range PCR followed by bidirectional sequencing of all coding regions and intron-exon boundaries of the GBA gene
  • GBA 8 Variants: Polymerase chain reaction (PCR) and fluorescence monitoring
    • Targeted variants: c.115+1G>A; c.84dupG, p.L29Afs; c.1226A>G, p.N409S; c.1263_1317del55; c.1297G>T, p.V433L; c.1342G>C, p.D448H; c.1448T>C, p.L483P; and c.1604G>A, p.R535H

Test Sensitivity and Specificity

Clinical Sensitivity

Sequencing: ~99% 

Targeted variants: 90% in individuals of Ashkenazi Jewish descent; 55% in other ethnicities 

Analytical Sensitivity and Specificity



  • Diagnostic errors can occur due to rare sequence variations.
  • Regulatory region variants, deep intronic variants, large deletions/duplications/insertions, gene conversion events and complex gene rearrangements may not be detected.
  1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999; 281(3): 249-54. PubMed
  2. Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE. 'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis. 2008; 31(3): 337-49. PubMed
  3. Pastores G, Hughes D. Gaucher Disease. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, eds. GeneReviews, University of Washington, 1993-2019. Seattle, WA [Last Update: Jun 2018; Accessed: Jul 2019]

Last Update: August 2019